Market research
HUGE FSD Pharma Inc Class B
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 67K
- P/E ratio
- Not available
- Analyst target
- 2.6
- Dividend yield
- Not available
- Beta
- 0.85
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA35954B2066
- Market cap
- 67K
- P/E ratio
- Not available
- Analyst target
- 2.6
- Dividend yield
- Not available
- Beta
- 0.85
About
About FSD Pharma Inc Class B
FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HUGE discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 92.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 105.0.
Based on the above factors, FSD Pharma Inc gets an overall score of 1/5.